These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 17617493)
1. Medication guides scrutinized. Young D Am J Health Syst Pharm; 2007 Jul; 64(14):1464-6. PubMed ID: 17617493 [No Abstract] [Full Text] [Related]
2. Regulating the safety of pharmaceuticals: the FDA, preemption, and the public's health. Gostin LO JAMA; 2009 May; 301(19):2036-7. PubMed ID: 19454642 [No Abstract] [Full Text] [Related]
12. Problems with medicine packages: experiences reported to a Dutch medicine reporting system. van Geffen EC; Meuwese E; Philbert D; Bouvy ML Ann Pharmacother; 2010 Jun; 44(6):1104-9. PubMed ID: 20442349 [TBL] [Abstract][Full Text] [Related]
13. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012. Cheng CM; Shin J; Guglielmo BJ JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107 [No Abstract] [Full Text] [Related]
14. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Zineh I; Gerhard T; Aquilante CL; Beitelshees AL; Beasley BN; Hartzema AG Pharmacogenomics J; 2004; 4(6):354-8. PubMed ID: 15483659 [No Abstract] [Full Text] [Related]
15. Show drugs work before selling them. Sipp D; McCabe C; Rasko JE Nature; 2017 Mar; 543(7644):174-175. PubMed ID: 28277530 [No Abstract] [Full Text] [Related]
16. Color coding of multisource products should be standardized or eliminated. Clifton GD; Record KE Am J Hosp Pharm; 1988 May; 45(5):1066. PubMed ID: 3400647 [No Abstract] [Full Text] [Related]
17. Manufacturing uncertainty: adverse effects of drug development for women. Peppin P Int J Law Psychiatry; 2003; 26(5):515-32. PubMed ID: 14522223 [No Abstract] [Full Text] [Related]
18. Therapeutic orphans: who speaks for children? Shirkey HC South Med J; 1970 Nov; 63(11):1361-3. PubMed ID: 5475304 [No Abstract] [Full Text] [Related]
19. Deterring inefficient pharmaceutical litigation: an economic rationale for the FDA regulatory compliance defense. Viscusi WK; Rowland SR; Dorfman HL; Walsh CJ Spec Law Dig Health Care Law; 1996 Mar; (205):9-52. PubMed ID: 10156421 [No Abstract] [Full Text] [Related]
20. What's in a drug name? Wick JY J Am Pharm Assoc (2003); 2004; 44(1):12-4. PubMed ID: 14965147 [No Abstract] [Full Text] [Related] [Next] [New Search]